Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Behavioural Brain Research
|
April 18, 2024
Perturbations in risk/reward decision making and frontal cortical catecholamine regulation induced by mild traumatic brain injury
Christopher P Knapp, Eleni Papadopoulos, Jessica A Loweth, et al.
Behavioural Brain Research
|
September 6, 2024
Sex-dependent perturbations in risky choice behavior and prefrontal tyrosine hydroxylase levels induced by repetitive mild traumatic brain injury
Christopher P Knapp, Eleni Papadopoulos, Jessica A Loweth, et al.
Psychopharmacology
|
June 7, 2011
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625
Karen L Marquis, Thomas A Comery, Flora Jow, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 8, 2009
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia
Steven M Grauer, Virginia L Pulito, Rachel L Navarra, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 21, 2010
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes
Michele P Kelly, Sheree F Logue, Julie Brennan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
Julie A Brennan, Radka Graf, Steven M Grauer, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
David P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.
Acta Anaesthesiologica Scandinavica
|
May 20, 2025
Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation (MAP-CARE): A protocol for a randomized clinical trial
V H Niemelä, M Reinikainen, N Nielsen, et al.
Acta Anaesthesiologica Scandinavica
|
April 3, 2025
Continuous deep sedation versus minimal sedation after cardiac arrest and resuscitation (SED-CARE): A protocol for a randomized clinical trial
A Ceric, J Dankiewicz, J Hästbacka, et al.
Acta Anaesthesiologica Scandinavica
|
April 10, 2025
Sedation, temperature and pressure after cardiac arrest and resuscitation-The STEPCARE trial: A statistical analysis plan
C B Kamp, J Dankiewicz, M Harboe Olsen, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Behavioural Brain Research
|
April 18, 2024
Perturbations in risk/reward decision making and frontal cortical catecholamine regulation induced by mild traumatic brain injury
Christopher P Knapp, Eleni Papadopoulos, Jessica A Loweth, et al.
Behavioural Brain Research
|
September 6, 2024
Sex-dependent perturbations in risky choice behavior and prefrontal tyrosine hydroxylase levels induced by repetitive mild traumatic brain injury
Christopher P Knapp, Eleni Papadopoulos, Jessica A Loweth, et al.
Psychopharmacology
|
June 7, 2011
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625
Karen L Marquis, Thomas A Comery, Flora Jow, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 8, 2009
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia
Steven M Grauer, Virginia L Pulito, Rachel L Navarra, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 21, 2010
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes
Michele P Kelly, Sheree F Logue, Julie Brennan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
Julie A Brennan, Radka Graf, Steven M Grauer, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
David P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.
Acta Anaesthesiologica Scandinavica
|
May 20, 2025
Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation (MAP-CARE): A protocol for a randomized clinical trial
V H Niemelä, M Reinikainen, N Nielsen, et al.
Acta Anaesthesiologica Scandinavica
|
April 3, 2025
Continuous deep sedation versus minimal sedation after cardiac arrest and resuscitation (SED-CARE): A protocol for a randomized clinical trial
A Ceric, J Dankiewicz, J Hästbacka, et al.
Acta Anaesthesiologica Scandinavica
|
April 10, 2025
Sedation, temperature and pressure after cardiac arrest and resuscitation-The STEPCARE trial: A statistical analysis plan
C B Kamp, J Dankiewicz, M Harboe Olsen, et al.
Page
of 4